Perrigo furthers commitment to Ireland
Dublin headquarters central to European and global growth strategy.
Perrigo Company has announced that a number of key public facing corporate functions will be relocated to Ireland as part of the company's focused international growth strategy and global expansion. This announcement furthers the company's previously announced actions on 22 October 2015 to maximize efficiency and continue leveraging the strength of Perrigo's global platform. A number of positions will also be added to the company's Dublin headquarters across a range of corporate functions including supply chain/global operations, procurement, enterprise risk management and corporate finance and information technology.
Perrigo has long identified Ireland as a gateway for its expansion into Europe. The acquisition of Omega Pharma in 2015, which added a pan-European branded consumer healthcare platform, the transfer of major corporate functions to Ireland, and the expansion of the Company's headquarters underscores Perrigo's commitment to European and international growth.
As part of this expansion, Arthur Shannon will relocate to Ireland and assume the role of Vice President, Global Corporate Affairs and European Investor Relations. In this role Mr Shannon will continue to oversee both internal and external Global Communications and will continue to be the lead point of contact for media. In addition, he will now be responsible for establishing a global government relations base from Dublin and expanding Perrigo's already robust, shareholder focused Investor Relations programs across Europe. Mr Shannon will be moving to Dublin in early April. At that time we will update his contact information.
Separately, Bradley Joseph has been promoted to the role of Vice President, Global Investor Relations. Mr Joseph will lead the investor relations team in designing and executing the relevant strategies, communications and investor outreach programs for the globe. He will continue to be based in Allegan, Michigan.
In addition, Lou Cherico, Vice President, Corporate Treasurer, will relocate to Dublin, to accelerate the buildout of Perrigo's Global Treasury and Risk Management functions in Ireland to better support our international expansion.
Msr. Shannon, Joseph and Cherico will report directly to Judy Brown, Executive Vice President and Chief Financial Officer at Perrigo.
Joe Papa, Chairman and CEO of Perrigo commented: "We are delighted to announce the addition of these key external facing corporate functions to our Dublin base, reinforcing our plans to expand our footprint in Ireland. These additions build on the outstanding Dublin based team currently in place. We are excited about this next chapter in our international growth. The enhancement of our Irish operations furthers the benefits of our global platform and will enable us to drive continued strong profit growth and enhance shareholder value."
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance